Gentium's Defibrotide Highlighted at American Society of Hematology Annual Meeting.

VILLA GUARDIA (COMO), Italy -- Gentium S.p.A. (NASDAQ:GENT) (the "Company") today reported that its lead investigational product, Defibrotide, will be the subject of 10 presentations and three publications at the American Society of Hematology's (ASH) 48th Annual Meeting and Exposition being held at the Orange County Conference Center in Orlando, Florida, December 9-12, 2006.

On Saturday, December 9, 2006, the following three poster presentations will be available for review from 9:00 a.m. to 7:30 p.m. in Hall E1:

* "Defibrotide Does Not Cross-React with HIT Antibodies. Implications in the Management of HIT;" (Board #182-I)

* "The South East England Thrombotic Thrombocytopenic Purpura Registry" (Board #192-I)

* "Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications" (Board #754-I)

On Sunday, December 10, 2006, from 4:30 p.m. to 6:00 p.m. in Room 312, Dr. Paul Richardson, M.D., Clinical Director of Dana-Farber Cancer Institute's Jerome Lipper Multiple Myeloma Center, Assistant Professor of Medicine at Harvard Medical School and the Principal Investigator for the U.S. Phase III trial of Defibrotide in Severe VOD, will present an Oral Session entitled, "Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial."

On Monday, December 11, 2006, the following six poster presentations will be available for review from 10:30 a.m. to 7:00 p.m. in Hall E1:

* "Defibrotide Effectively Prevents Veno-Occlusive Disease of the Liver (VOD) after Allogeneic Stem Cell Transplantation. An Extended Study." (Board #191-III)

* "High Dose Defibrotide as Therapy for Pediatric Patients with Veno-Occlusive Disease of the Liver." (Board #192-III)

* "Prophylactic Defibrotide in Allogeneic Stem Cell Transplantation: Low Morbidity and Zero Mortality from Veno-Occlusive Disease." (Board #197-III)

* "In Vitro Monitoring of Defibrotide Prophylaxis for Endothelial Complications Following Allogeneic Stem Cell Transplantation." (Board #198-III)

* "Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications." (Board #752-III)

* "A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced Multiple Myeloma Patients." (Board #789-III)

The following three studies will be available in publication form at the meeting:

* "Stem Cell Transplantation in Children with Infantile Osteopetrosis Is Associated with a High Incidence of VOD, Which Could Be Prevented with Defibrotide."

* "Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease in Children."

* "Monitoring Immune Function by the Cylex Immuknow Assay in Pediatric HSCT Patients."

Laura Ferro, M.D., Gentium's president and chief executive officer, said, "We are very proud to have Defibrotide highlighted in such an extensive mix of oral sessions, poster presentations and publications at this year's ASH meeting. The volume of clinical data being presented underscores the potential therapeutic value of Defibrotide in a growing number of important clinical indications, including for the treatment and prevention of VOD and for the treatment of multiple myeloma.

"We are particularly pleased with the data to be discussed at ASH from an independent Phase I/II study of Defibrotide to treat multiple myeloma in combination with melphalan, prednisone and thalidomide underway in Italy. These positive top-line results from the Phase I segment of this trial are very encouraging, and we look forward to the commencement of the Phase II segment of this study.

"We continue to make progress with our U.S. Phase III trial of Defibrotide to treat Severe VOD, and look forward to building upon the compelling results from our U.S. Phase II study of Defibrotide to treat this devastating and often fatal disease," concluded Dr. Ferro.

About Gentium

Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the research, discovery and development of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status and Fast Track Designation by the U.S. Food and Drug Administration to treat Severe Veno-Occlusive disease (VOD) and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F for the year ended December 31, 2005 under the caption "Risk Factors."

Source: Gentium